Available online at www.sciencedirect.com

SciVerse ScienceDirect

journal homepage: www.elsevier.com/locate/ihj

Original article

Risk factors for contrast induced nephropathy: A study among Italian patients

Salvatore Evola, Monica Lunetta, Francesca Macaione*, Giuseppe Fonte, Gaspare Milana, Egle Corrado, Francesca Bonura, Giuseppina Novo, Enrico Hoffmann, Salvatore Novo

Division and Post-Graduate School of Cardiology, Center for the Early Diagnosis of Preclinical and Multifocal Atherosclerosis and for the Secondary Prevention, University Hospital "P. Giaccone" of the University of Palermo, Via del Vespro 127-90127, Italy

ARTICLE INFO

Article history:

Received 26 March 2012

Received in revised form

11 May 2012

Accepted 17 July 2012

Available online 27 July 2012

Keywords:

Contrast induced nephropathy

Atherosclerosis

Percutaneous coronary intervention

Coronary angiography

ABSTRACT

This study aimed to make a profile of patients at highest risk of developing contrast induced nephropathy (CIN) in order to take appropriate prevention measures. 591 patients undergoing coronary procedures were divided into two groups: patients with (CIN-group) and without (no-CIN) an increase in creatinine level equal or more than 25% from baseline values within 24–48 h after the coronary procedure. All patients underwent an accurate anamnesis, objective exam, hematocchemical measurements, and diagnostic exams. The results of this study while confirming that, average age ($p = 0.01$), diabetes mellitus ($p < 0.0001$), base line renal insufficiency ($p = 0.0001$), diuretic therapy ($p = 0.002$), higher contrast doses ($p = 0.01$), are associated with a higher risk of contrast-induced nephropathy, also demonstrated that both clinical ($p = 0.01$) and subclinical ($p < 0.0001$) atherosclerosis, and higher preprocedural high sensitive C-reactive protein levels (hs-CRP) ($p = 0.02$) are risk factors for CIN.

Copyright © 2012, Cardiological Society of India. All rights reserved.

1. Introduction

Contrast-induced nephropathy (CIN) is the third leading cause of hospital-acquired acute renal failure, accounting for 10% of all cases of hospital-acquired renal failure.¹ It is commonly defined as an acute deterioration of the renal function characterized by a significant increase in serum creatinine levels, usually more than 0.5 mg/dl (44 μ mol/L) or 25% of baseline levels, within 24–48 h after exposure to a contrast agent compared to baseline serum creatinine values, when alternative explanations for renal impairment have been excluded.² The CIN is associated with increased mortality and

morbidity and costs,^{3–5} in fact, although usually transient, its resolution needs 1–3 weeks on average, the impairment of renal function may be permanent in some cases with the risk of progression towards chronic renal failure and the necessity of a temporary or permanent dialysis.⁶ Prevention is the key to reduce the incidence of CIN and it begins with identification of the high risk patient coupled with appropriate peri-procedural management. Many studies have been conducted to identify the main risk factors for CIN, in fact many score systems have been proposed^{7–12} and increasing number of guidelines have been suggested in literature^{13,14} to help lessen the complication of CIN.

* Corresponding author. Chair of Cardiovascular Disease, Division and Post-Graduate School of Cardiology, Center for the Early Diagnosis of Preclinical and Multifocal Atherosclerosis and for the Secondary Prevention, University Hospital "P. Giaccone" of the University of Palermo, Via del Vespro 127-90127, Italy. Tel.: +39 329 0054524; fax: +39 091 6554301.

E-mail address: francescamac85@libero.it (F. Macaione).

0019-4832/\$ – see front matter Copyright © 2012, Cardiological Society of India. All rights reserved.

<http://dx.doi.org/10.1016/j.ihj.2012.07.007>

A strong correlation was found between risk of CIN and pre-existing renal impairment, diabetes mellitus, advanced age, peri-procedural dehydration congestive heart failure, volume and type of contrast administered, and concomitant use of other nephrotoxic drugs.^{5,7,15} Few studies have, however investigated the role of systemic inflammation and extracardiac atherosclerosis as possible independent predictors of CIN. Some recent studies found that elevated pre-procedural C-reactive protein (CRP) levels may be associated with an increased risk for CIN after percutaneous coronary intervention (PCI).^{16,17}

The aim of our study was to make a profile of patients at highest risk of developing CIN after coronary angiography and/or percutaneous coronary intervention, in order to take appropriate prevention measures, analyzing the risk factors, evaluated extensively in the literature, and assessing if other markers of inflammation and atherosclerosis, may be considered as risk factors for CIN.

2. Material and methods

2.1. Study population

In our clinical experience we assessed a population composed of 1300 consecutive patients undergoing coronary angiography and, if necessary, elective or emergency percutaneous coronary intervention from October 2006 to June 2008 in Center for the Early Diagnosis of Preclinical and Multifocal Atherosclerosis and for the Secondary Prevention, University Hospital “P. Giaccone” of the University of Palermo–Italy. We excluded the patients admitted in other departments after procedures, making it very difficult to monitor their clinical condition and to perform biochemical analysis pregnancy, underwent coronary artery by pass graft (CABG) within 48 of coronary angiography/angioplasty non availability of CRP and serum creatinine levels at admission with life expectancy <1 year. Patients were also excluded if they had concomitant inflammatory conditions (such as active infection, inflammatory arthritis or connective tissue disease) or malignancies or had recent (<4 months) surgery or major trauma.

In this manner, a final sample size of 591 (45.46%) of 1300 patients were enrolled and underwent detailed history, thorough examination, biochemical and haematological analysis, ultrasonographic examination of carotid arteries and ankle-brachial index evaluation.

The database compiled for each patient contains the data listed in Table 1.

Family history of CAD (Coronary artery disease) was defined as a coronary event occurring before 55 and 65 years, for first-degree male and female relatives respectively. Diabetes mellitus was defined as a fasting glucose ≥ 126 mg/dl on at least two separate occasions or as the use hypoglycemic drugs.¹⁸ Hypertension was defined as a blood pressure $>140/90$ mmHg or as use antihypertensive drugs. Present smokers if they were current smokers or had stopped for less than 1 year. Obesity was defined as a body mass index ≥ 30 kg/m². Anemia was defined as hemoglobin level less than 13 g/dl in men and less than 12 g/dl in women.¹⁹ Dyslipidemia defined as plasma triglycerides >150 mg/dL and/or plasma low-density

lipoprotein cholesterol (LDL-C) >130 mg/dL and or plasma (high-density lipoprotein-cholesterol) HDL-C <40 mg/dL in men and <50 mg/dL in women. Multivessel CAD was defined as two or more lesion ($>50\%$) in different epicardial coronary arteries.

The presence of extracoronary atherosclerosis was demonstrated by echo-color Doppler exams and measurement of ABI (Ankle Brachial Pressure) performed before or during stay in hospital, taking into account any site: carotid vessels and inferior limbs. In our study we considered the term of extracoronary atherosclerosis both for clinical and preclinical atherosclerosis.

Chronic Renal Insufficiency (CRI), assessed at admission, was defined as an estimated Glomerular Filtration Rate (eGFR) below 60 mL/min/1.73 m² square and calculated using a modified MDRD equation.

All patients were closely monitored during their stay in hospital to assess their creatinine serum peak 3–4 days after contrast procedure: if subjects were discharged earlier, they were advised to undergo a blood sample privately and to inform us the results. Two groups of patients were individualized in the study population: age according to percentage variation of serum creatinine between the pre and the post procedural phase: “CIN-group” and “no-CIN group”.

CIN was defined as an absolute increase in serum creatinine of 25% from baseline values occurring within 24–48 h after the coronary procedure.²

2.2. Biochemistry

A blood sample was drawn in the morning, before the medical examination, after a 12–14 h overnight fast. Total cholesterol (TC), triglycerides (TG), and HDL-cholesterol were quantified by standard enzymatic-colorimetric methods²⁰ and LDL-cholesterol was calculated by Friedewald’s method.

The patients had blood drawn for hs-CRP analysis immediately before primary coronary intervention.

High sensitive (hs)-CRP was determined by the nephelometric method (Beckman Instrument APS).²¹

Fibrinogen determination was rapidly performed according to the coagulative method of Clauss.²²

2.3. Echocolor Doppler examination of carotid arteries

B-mode real-time ultrasound (Toshiba 270 SS) was performed to evaluate the arterial wall thickness in the carotid arteries using a probe of 7.5–10.0 MHz. As already reported^{23,24} patients were examined in the supine position and each carotid wall or segment was examined to identify the thickest intimal-medial site. Each scan of the common carotid artery began just above the clavicle, and the transducer was moved until the carotid bifurcation and along the internal carotid artery. Three segments were identified and measured in antero and posterior planes on each side: the distal 1.0 cm of the common carotid proximal to the bifurcation, the bifurcation itself, and the proximal 1.0 cm of the internal carotid artery. At each of these sites we detected any possible plaque and determined the IMT as defined as the distance between the echogenic line representing the intima blood interface

Table 1 – Main characteristics between “CIN-group” and “no-CIN group”. Results of univariate analysis.

	No-CIN (n = 486)	CIN (n = 105)	p value <0.05
Demographic characteristics			
Mean age	65.32 ± 12.02	68.94 ± 11.31	0.004
Male n (%)	69.3% (337)	69 (65.7)	0.54
Clinical characteristics n (%)			
Diabetes mellitus	150 (30.9%)	44 (42%)	0.03
Smoke	141 (29.0%)	30 (28.6%)	0.97
Ex smoke	132 (27.2%)	22 (20.9%)	0.23
Dyslipidemia	233 (47.9%)	53 (50.5%)	0.72
Family history	189 (38.9%)	45 (42.8%)	0.51
Arterial hypertension	340 (69.9%)	83 (80.0%)	0.05
Anemia	50 (10.3%)	19 (18.1%)	0.03
Previous CRI	61 (12.5%)	28 (26.6%)	<0.001
Obesity (BMI >30 kg/m ²)	72 (14.8%)	23 (21.9%)	0.09
Previous CABG	39 (8.0%)	14 (13.3%)	0.12
Previous IMA	138 (28.4%)	33 (31.4%)	0.61
Previous AF	42 (8.6%)	9 (8.6%)	0.86
Previous PCI	130 (26.7%)	23 (21.9%)	0.36
Previous HF	24 (4.9%)	7 (6.7%)	0.63
Valvular disease	36 (7.4%)	3 (2.8%)	0.13
Thyroid disease	32 (6.6%)	4 (3.8%)	0.39
Diabetic complication	18 (3.7%)	2 (1.9%)	0.53
Thromboembolic disease	1.0% (5)	2 (1.9%)	0.79
Biological characteristics			
Total cholesterol (mg/dl)	171.52 ± 44.12	168.7 ± 41.56	0.56
HDL cholesterol (mg/dl)	43.26 ± 11.89	41.68 ± 12.86	0.22
LDL cholesterol (mg/dl)	100 ± 38.09	104.29 ± 37.73	0.29
Triglycerides (mg/dl)	134.24 ± 73.03	135.79 ± 79.50	0.85
Inflammatory markers			
Hs-CRP (mg/L)	1.63 ± 5.5	2.84 ± 4.27	0.03
ESR (mm/h)	17.36 ± 16.67	28.94 ± 21.14	<0.001
Fibrinogen (mg/dl)	368.42 ± 98.15	394.91 ± 113.99	0.02
Diagnosis extracoronary ATS n (%)			
Clinical ATS n (%)	215 (44.2%)	68 (64.8%)	<0.001
Preclinical ATS n (%)	148 (30.4%)	44 (41.9%)	0.03
	67 (13.8%)	24 (22.9%)	0.02
Medications n (%)			
Diuretics	106 (21.8%)	37 (35.2%)	0.005
Ace-inhibitors	253 (52.1%)	61 (58.1%)	0.31
Sartans	114 (23.4%)	24 (22.8%)	0.99
Statins	366 (75.3%)	85 (80.9%)	0.26
NSAIDs	414 (85.2%)	90 (85.7%)	0.98
Angiography characteristics			
Emergency procedure n (%)	66 (11.16%)	30 (28.6%)	<0.001
Bare metal stent n (%)	263 (54.11%)	58 (55.23)	0.91
N°stents	1.44 ± 0.60	1.45 ± 0.55	0.87
Type of contrast media n (%)			
Iodixanol (Visipaque)	320 (65.8%)	71 (67.6%)	0.81
Iomeprol (Iomeron)	94 (19.3%)	20 (19.0%)	0.94
Ioversol (Optiray)	72 (14.8%)	14 (13.3%)	0.81
Mean doses of contrast media (cc)	115.1 ± 83.56	136.9 ± 101.73	0.02
Multivessel disease n (%)			
0 sick vessels n (%)	200 (41.15%)	45 (42.85)	0.83
1 sick vessel n (%)	115 (23.6%)	18 (17.1%)	0.18
2 sick vessels n (%)	151 (31.0%)	35 (33.3%)	0.73
3 sick vessels n (%)	108 (22.2%)	20 (19%)	0.55
Common trunk n (%)	100 (20.6%)	27 (25.7%)	0.29
	28 (5.8%)	10 (1.7%)	0.13

CRI, chronic renal insufficiency; CABG, coronary artery by pass graft; IMA, acute myocardial infarction; AF, atrial fibrillation; PCI, percutaneous coronary intervention; HF, heart failure; HDL, high density lipoprotein; LDL, low density lipoprotein; hs-CRP, high sensitivity C reactive protein; ESR: erythrocyte sedimentation rate; ATS, atherosclerosis; ACE, angiotensin converting enzyme; NSAIDs non steroidal anti-inflammatory drugs.

and the outer echogenic line representing the adventitia junction.

Subjects with subclinical carotid atherosclerosis were considered, in accordance to the joint ESH/ESC guidelines, in

relation to the ultrasound report, both subject with intima-media thickening (with IMT >0.9 mm and <1.5 mm) and subjects with asymptomatic carotid plaque (APC) (IMT >1.5 mm).²⁵

2.4. Ankle-brachial index measurement

Measurement of Ankle-Brachial Index (ABI) is an easy-to-perform, inexpensive, reproducible and non-invasive test.¹⁹ It was performed with the patient supine; systolic blood pressure was recorded at both arms and both ankles with an Esaote Caris Plus ultrasound scanner using a 7.5–10.0 MHz linear probe.

ABI was calculated for each leg by dividing the highest ankle pressure by highest pressure of both arms. An ABI <0.90 is widely accepted as a reasonable cut point to confirm the diagnosis of preclinical atherosclerosis of arteries supplying the legs.²⁶

2.5. Statistical analysis

Continuous variables were presented as mean $\pm$ SD and compared using Student's *t* test. In case of non normal distribution, non parametric methods were used (Mann–Whitney *U* test). Categorical variables were presented as counts and percentages and compared with χ^2 -test when appropriate (expected frequency >5). Otherwise, Fisher's exact test was used. *p* value <0.05 was considered statistically significant. To identify independent characteristics associated with CIN multivariable logistic regression analysis was used. Results of this model were presented as Odds Ratio (OR) and 95% confidence intervals (95% CI) for OR. Models were developed with stepwise techniques and by consideration of potential confounding factors and of variables that are shown to be statistically significant at univariate analysis. All data was processed using MedCalc software version 11.3.0.0.

3. Results

The study population consisted of 591 patients with a mean age 65.96 ± 11.31 years, 406 (68.69%) were men.

The patient sample was divided up into 2 groups: "CIN-group" and "no-CIN group".

The "no-CIN group" included a total of 486 patients, 337 males (69.3%) and 149 females (30.7%) with average age 65.32 ± 12.02 years [Table 1].

The CIN group included a total of 105, 69 males (65.7%) and 36 females (34.3%) with average age 68.94 ± 11.31 years [Table 1].

The main clinical characteristics of the patient population are summarized in Table 1.

After univariate analysis, by analyzing different features, the CIN and no-CIN groups resulted to be fully homogeneous for the characteristics reported in Table 1 ($p > 0.05$).

On the contrary, as reported in Table 1, it emerged that patients of CIN group were older individuals than controls (68.94 ± 11.31 versus 65.32 ± 12.02 years, respectively; $p = 0.004$) and had significantly higher proportion of diabetes ($p = 0.03$), renal insufficiency ($p < 0.001$), emergency procedure ($p < 0.001$), therapy with diuretics ($p = 0.005$), anemia ($p = 0.03$) compared with patients of "no-CIN group", while arterial blood pressure was limit of significance ($p = 0.05$).

As regards cardiology procedures, in subjects who developed CIN a higher dose of contrast media was administered

($p = 0.02$), while the compared analysis of the patient groups in relation to the molecule type chosen to make coronaries opaque (iodixanol, iomeprol, ioversol), did not show any significant statistical difference.

An interesting relationship was found between systemic inflammation and extent of coronary atherosclerosis: an increase in blood levels of hs-CRP and fibrinogen, corresponded to a proportional increase in the number of diseased vessels [Figs. 1 and 2], this result could suggest a possible direct connection between this latest data and risk of CIN but this correlation is not statistically confirmed in univariate analysis (multivessel disease $p = 0.83$; 2 sick vessels $p = 0.55$; 3 sick vessels $p = 0.29$) [Table 1].

Moreover a statistically significant difference was found between the two groups for preprocedural CRP levels ($p = 0.03$), serum fibrinogen levels ($p = 0.015$) and erythrocyte sedimentation rate (ESR) ($p < 0.001$), particularly an increase of blood levels of hs-CRP corresponded to a proportional increase of CIN [Fig. 3].

Another important finding is that both clinical ($p = 0.03$) and preclinical ($p = 0.02$) extracoronary atherosclerosis was more represented in the CIN group.

After we made a multivariate analysis to identify independent factors associated with contrast induced nephropathy, considering the variables that univariate analysis showed statistically significant difference (diabetes, diuretics, mean doses of contrast media, anemia, emergency procedure, inflammatory markers, extracoronary atherosclerosis, chronic renal insufficiency) and the potential confounding factors such as multivessel disease, sex, hypertension, type of contrast media, number of stent. From the logistic regression analysis age (OR = 1.03; 95%CI 1.01 to 1.05; $p = 0.01$), diabetes mellitus (OR = 3.04; 95%CI 1.81 to 5.10; $p < 0.0001$), treatment with diuretic (OR = 1.04; 95%CI 1.02 to 1.07; $p = 0.002$), dose of contrast (OR = 1.84; 95%CI 1.14 to 2.99; $p = 0.01$); CRP serum levels (OR = 1.92; 95%CI 1.10 to 3.36; $p = 0.02$), extracoronary atherosclerosis both clinical (OR = 1.84; 95%CI 1.16 to 2.94; $p = 0.010$) preclinical atherosclerosis (OR = 4.10; 95%CI 2.19 to 7.70; $p < 0.0001$) and previous chronic renal insufficiency (CRI) (OR = 2.77; 95%CI 1.67 to 4.60; $p = 0.0001$), were independent predictors of the CIN [Table 2].

Fig. 1 – Linear relationship between fibrinogen serum levels and number of sick vessels.

Fig. 2 – Linear relationship between hs-CRP serum levels and number of sick vessels.

4. Discussion

Contrast induced nephropathy (CIN) is a feared complication of radiological procedures that expose patients to contrast media. Although the risk of renal function impairment associated with radiologic procedures is low in the general population, it may be very high in selected patient subsets, especially in cardiac procedures^{6,15,27} such as percutaneous coronary intervention (PCI) and coronary angiography. Not only is this a leading cause of morbidity and mortality, but it also adds to increased costs in high risk patients undergoing percutaneous coronary intervention.

In our clinical experience we evaluated a patient population, dividing it into two arms according to the onset of contrast induced nephropathy after coronarography and/or percutaneous angioplasty.

By statistical analysis of baseline characteristics of study population, some peculiar factors seemed to be strongly correlated to the risk of developing CIN.

Fig. 3 – Linear relationship between hs-CRP serum levels and CIN (contrast induced nephropathy).

Table 2 – Independent correlates of CIN.

	OR	95% CI		p value
		Lower	Upper	
Age	1.03	1.01	1.05	0.01
Diabetes mellitus	3.04	1.81	5.10	<0.0001
Diuretics	1.04	1.02	1.07	0.002
Mean doses of contrast media (cc)	1.84	1.14	2.99	0.01
Hs-CRP (mg/L)	1.93	1.10	3.36	0.02
Diagnosis extracoronary ATS				
Clinical ATS	1.85	1.16	2.94	0.01
Preclinical ATS	4.11	2.19	7.70	<0.0001
Previous CRI	2.77	1.67	4.60	0.0001

Hs-CRP, high sensitivity C reactive protein; ESR: erythrocyte sedimentation rate; ATS, atherosclerosis; CRI, chronic renal insufficiency.

The incidence of CIN is considerably higher in elderly patients, in patients affected by diabetes mellitus, kidney failure, undergoing diuretic therapy, treated with higher contrast doses than the general population, according to literature data^{5,7,15,28} and in patients with a state of systemic inflammation and extra cardiac atherosclerosis both clinical and preclinical. The elderly remain at a higher risk of CIN after PCI, a few studies have found age older than 70 years to be an independent predictor of CIN in multivariate analysis.²⁹ Mehran et al, similarly, found eight variables for patients who underwent PCI (hypotension, intra-aortic balloon pump, congestive heart failure, chronic kidney disease, diabetes, age 75 years, anemia, and volume of contrast) and assigned a weighted integer to each variable to make up a score cumulatively so as to divide low risk (5) and high risk (16) scores.⁷ Many studies have found Diabetes Mellitus (DM) as an independent risk factor for CIN.^{5,15,30} Toprak et al showed that in patients with preexisting renal insufficiency, Diabetes Mellitus independently increased the risk of development of CIN and need for dialysis as opposed to pre-DM and Normal Fasting states,³¹ while Berns showed that the incidence of CIN in diabetics was increased if serum creatinine is more than 4.0 mg% compared to 2 to 4 mg%. Clearly, there is a synergistic effect of diabetes and pre existing renal insufficiency.³²

As expected, the presence of a previous renal insufficiency, defined as an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m², turned out to be a very sensitive index of CIN.^{6,33} Based on the available evidence in the literature the risk of CIN is inversely related to the calculated estimated GFR (eGFR).¹⁵

Studies have shown that diuretics and mannitol have no beneficial effects and may be harmful^{34,35} and their use cannot be recommended for CIN prophylaxis. In fact the use of loop diuretics may actually exacerbate post-procedural renal function.³⁶ On the other hand preprocedure hydration seems to be the best strategy for preventing CIN.^{13–37}

Our data showed that the CIN risk increases proportionally to the doses of contrast media. Intuitively, the less contrast media administered, the lower the risk for CIN, in fact volume of contrast remains the primary modifiable risk factor.³⁸ Many studies have documented a clear correlation

between volume of contrast and risk of CIN.^{38,39} However, whether incidence of CIN is dose related or not has also been studied. In their study, Mekan et al found that the contrast-induced reduction in renal function was not significantly higher with a higher volume of contrast (100 mL).⁴⁰ On the other hand, Kane et al demonstrated a significant rise in incidence of CIN with increase of volume of contrast.³⁸ Although the pathogenesis of this condition is not fully understood, it is most likely the result of the prolonged vasoconstriction, for alterations in nitric oxide metabolism that lead to renal vasoconstriction, and impaired autoregulation induced by contrast media predispose to medullary hypoxia, in combination with direct cytotoxicity to the renal tubular epithelium. This may be further influenced by contributions from several systemic factors, in fact the damage may be mediated by formation of free radicals in the acidic tubular environment.⁴¹ Therefore, an appreciation of the factors affecting renal microcirculatory hemodynamics is pivotal to understanding the pathogenesis of CIN and the expected response to preventive measures.

In particular, the hemodynamic theory of CIN pathophysiology would be indirectly confirmed by another datum we found, that is, the higher predisposition to CIN occurrence in subjects undergoing emergency CVG or PCI. In fact contrast-induced nephropathy frequently complicates primary PCI, even in patients with normal renal function.⁴² Actually, the acute cardiocirculatory failure of these patients could cause a contrast-induced damage both by worsening kidney hypoperfusion and by preventing to take appropriate preventive measures before intervention. The type of molecule used as contrast media was not a differential factor between the two groups: this is easily understandable considering that in our hemodynamic laboratory only low-osmolar non ionic monomers or iso-osmolar ionic and non-ionic dimers are used, in accordance with the latest evidences on the least dangerous molecules for the kidney.^{43,44}

Another very interesting aspect that came up from our study concerns the role of systemic inflammation.

Although at multivariate analysis, the fibrinogen levels and erythrocyte sedimentation rate (ESR) were not independent predictors, elevated pre-procedural C-reactive protein was a strong and independent predictor of CIN.

Recent studies have reached similar results, despite few studies have investigated hs-CRP as a risk factor for contrast-induced nephropathy. Gao et al in their study demonstrated that elevated preprocedural CRP was associated with an increased risk for CIN in patients undergoing PCI.¹⁶ Lyu et al showed that CRP was a significant and independent predictor of CIN after primary PCI in patients with STEMI.¹⁷ Some studies indicated that the administration of statins was associated with reduced incidence of CIN in patients undergoing PCI and the beneficial effect of statins on systemic inflammation and endothelium dysfunction has been well documented.^{45,46}

Furthermore, when the degree of systemic inflammation increased, the number of sick vessels increased too, confirming a trend of recent evidences linking hs-CRP to atherosclerotic disease.^{47,48} On the basis of these results, we wondered if there was also a direct relationship between the

number of sick vessels and the CIN risk, but this datum was not statistically proved. Moreover, despite the fact that no firm conclusions can be drawn at this stage, it has emerged from our study that extracoronary atherosclerosis both preclinical and clinical, may be another strongly predictive index of CIN and this could confirm the hypothesis, made by some authors,⁴⁹ that atherosclerosis is the actual link between cardiovascular and renal diseases, even considering the worse cardiovascular outcome of patients who develop CIN.^{10,50} In fact, the systemic inflammatory process, of which atherosclerosis is an expression, may induce alterations in the renal microcirculation, predisposing to CIN. Although the total number of patients with atherosclerosis preclinical in the two groups is very small, the role of preclinical atherosclerosis, as predictor of CIN, should not be underestimated: the preclinical atherosclerosis, if left to its free evolution, may lead to an increased susceptibility to CIN. It follows that IMT and ABI if properly interpreted, becomes an early indicator of damage.

An interesting fact was that after a multivariate analysis, anemia was not a risk factor, contrary to previous studies,^{7–9} probably because of the small percentage of subjects with anemia in this cohort.

Our study has some limitations: the study included a small population, admitted to a single center, due to limited availability of data fields, we could not consider periprocedural hydration volume, proteinuria, urine output, intra-aortic balloon pump in our multivariate analysis. In our institution, prophylactic use of sodium bicarbonate or N-acetylcysteine infusion is extremely rare due to their conflicting clinical results, so they were unavailable for our analyses. In addition the impossibility to conclude causality or exclude unmeasured confounding as a contributor to the observed association, we cannot exclude the presence of a selection bias and the possibility that other factors, might have contributed, at least in part, to renal impairment, and influenced the clinical outcome of our patients.

5. Conclusions

The findings of this study on one hand, according to literature data, provides further epidemiological evidence that, diabetes mellitus, volume of contrast media, diuretics, kidney failure are associated with a higher risk of contrast-induced nephropathy, on the other suggest that patient with high levels of CRP and extra cardiac atherosclerosis may be more exposed to CIN. It follows that IMT, ABI and above all, pre-procedural CRP level if properly interpreted, becomes an early indicator of CIN.

Pending further studies to confirm these results, in light of these data, it would be important to be able to better define the role of both preprocedural CRP level and atherosclerosis with respect CIN and to assess if preprocedural risk stratification with these factors as an adjunct to established clinical risk factors, further confirmed in our study, may be useful as form of prevention for early identification of high risk patients for CIN. Research now in progress will almost certainly help clarify the picture.

Conflicts of interest

All authors have none to declare.

REFERENCES

- Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. *Am J Kidney Dis*. 2002;39:930–936.
- Rudnik MR, Berns JS, Cohen RM, Goldfarb S. Contrast-media associated nephrotoxicity. *Semin Nephrol*. 1997;17:15–26.
- Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. *Circulation*. 2006;113:1799–1806.
- Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium. *N Engl J Med*. 2006;354:379–386.
- McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors and relationship to mortality. *Am J Med*. 1997;103:368–375.
- Gruberg L, Mehran R, Dangas G, et al. Acute renal failure requiring dialysis after coronary interventions. *Catheter Cardiovasc Interv*. 2001;52:417–419.
- Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol*. 2004;44:1393–1399.
- Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. *Am J Cardiol*. 2004;93:1515–1519.
- Bouzas-Mosquera A, Vasquez-Rodriguez JM, Calviño-Santos R, et al. Contrast-induced nephropathy and acute renal failure following emergent cardiac catheterization: incidence, risk factors, and prognosis [in Spanish]. *Rev Esp Cardiol*. 2007;60:1026–1034.
- Herts BR, Schneider E, Poggio ED, et al. Identifying outpatients with renal insufficiency before contrast-enhanced CT by using estimated glomerular filtration rates versus serum creatinine levels. *Radiology*. 2008;248:106–113.
- Maioli M, Toso A, Gallopin M, et al. Preprocedural score for risk of contrast-induced nephropathy in elective coronary angiography and intervention. *J Cardiovasc Med (Hagerstown)*. 2010;11:444–449.
- Schweiger MJ, Chambers CE, Davidson CJ, et al. Prevention of contrast induced nephropathy: recommendations for the high-risk patient undergoing cardiovascular procedures. *Catheter Cardiovasc Interv*. 2007;69:135–140.
- Ghani AA, Tohamy KY. Risk score for contrast induced nephropathy following percutaneous coronary intervention. *Saudi J Kidney Dis Transpl*. 2009;20:240–245.
- Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons; endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. *J Am Coll Cardiol*. 2008;51:171–253.
- Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. *Circulation*. 2002;105:2259–2264.
- Gao F, Zhou YJ, Zhu X, et al. C-reactive protein and the risk of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. *J Am Nephrol*. 2011;34:203–210.
- Liu Y, Tan N, Zhou YL, et al. High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention. *J Nephrol*. 2011.
- American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care*. 1997;20:1183–1197.
- World Health Organization. *Nutritional Anemia: Report of a WHO Scientific Group*. Geneva, Switzerland: World Health Organization; 1968.
- Murata M, Ide T. Determination of cholesterol in sub-nanomolar quantities in biological fluids by high-performance liquid chromatography. *J Chromatogr*. 1992;579:329–333.
- Montagne P, Laroche P, Cuilliere ML, Varcin P, Duheille J. Microparticle-enhanced nephelometric immunoassay for human C-reactive protein. *J Clin Lab Anal*. 1992;1:24–29.
- Von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. *Acta Haematol*. 1957;17:231–237.
- Corrado E, Rizzo M, Tantillo R, Muratori I, Bonura F, Vitale G, Novo S. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5 years follow-up study. *Stroke*. 2006;37:482–486.
- Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall. A direct measurement with ultrasound imaging. *Circulation*. 1986;74:1399–1406.
- Mancia G, De Backer G, Dominiczak A, et al. The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. *Eur Heart J*. 2007;28:1462–1536.
- De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). *Eur J Cardiovasc Prev Rehabil*. 2003;10:S1–S78.
- Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. *BMJ*. 1996;313:1440.
- Iakovou G, Dangas G, Mehran R, et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. *J Invasive Cardiol*. 2003;15:18–22.
- Marenzi G. La prevenzione della nefropatia da mezzo di contrasto e la gestione del paziente a rischio. *G Ital Cardiol*. 2009;10:88–96.
- Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. *Am J Cardiol*. 2005;95:13–19.
- Toprak O, Cirit M, Yesil M, et al. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease. *Nephrol Dial Transplant*. 2007;22:819–826.
- Berns S. Nephrotoxicity of contrast media. *Kidney Int*. 1989;36:730–740.
- Chen SL, Zhang J, Yei F, et al. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine. *Int J Cardiol*. 2008;126:407–413.

34. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of radiocontrast induced nephropathy clinical evaluation. *J Am Coll Cardiol*. 1999;33:403–411.
35. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. *N Engl J Med*. 1994;331:1416–1420.
36. Vlietstra RE, Nunn CM, Narvarte J, Browne KF. Contrast nephropathy after coronary angioplasty in chronic renal insufficiency. *Am Heart J*. 1996;132:1049–1050.
37. Bader BD, Berger ED, Heede MB, et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? *Clin Nephrol*. 2004;62:1–7.
38. Rosovsky MA, Rusinek H, Berenstein A, Basak S, Setton A, Nelson PK. High-dose administration of nonionic contrast media: a retrospective review. *Radiology*. 1996;200:119–122.
39. Kane GC, Doyle BJ, Lerman A, Barsness GW, Best PJ, Rihal CS. Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. *J Am Coll Cardiol*. 2008;51:89–90.
40. Mekan SF, Rabbani MA, Azhar-Uddin M, Ali SS. Radiocontrast nephropathy: is it dose related or not? *J Pakistan Med Assoc*. 2004;54:372–374.
41. Wellman TL, Jenkins J, Penar PL, Tranmer B, Zahr R, Lounsbury KM. Nitric oxide and reactive oxygen species exert opposing effects on the stability of hypoxia-inducible factor-1 α (HIF-1 α) in explants of human pial arteries. *FASEB J*. 2004;18:379–381.
42. Davidson CJ, Hlatky M, Morris KG, et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial. *Ann Intern Med*. 1989;110:119–124.
43. Feldkamp T, Baumgart D, Elsner M, et al. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients. *Clin Nephrol*. 2006;66:322–330.
44. Nie B, Cheng WJ, Li YF, et al. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention. *Catheter Cardiovasc Interv*. 2008;72:958–965.
45. Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. *Am J Cardiol*. 2008;101:279–285.
46. Xinway J, Xianghua F, Jing Z, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. *Am J Cardiol*. 2009;104:519–524.
47. Rizzo M, Corrado E, Coppola G, Muratori I, Novo G, Novo S. Markers of inflammation are strong predictors of subclinical and clinical atherosclerosis in women with hypertension. *Coron Artery Dis*. 2009;20:15–20.
48. Corrado E, Novo S. Evaluation of C-reactive protein in primary and secondary prevention. *J Investig Med*. 2007;55:430–438.
49. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. *N Engl J Med*. 2004;351:1285–1295.
50. Kowalczyk J, Lenarczyk R, Kowalski O, et al. Risk stratification according to the type of impaired renal function in patients with acute myocardial infarction treated with percutaneous coronary intervention. *Kardiologia Pol*. 2007;65:635–643.